Moreover, the results of an important preclinical study by Pirovano et al. provided the first full characterization of an auger-emitting PARP inhibitor, which showed a survival benefit in mouse models of GBM and verified the high potential of 123I-MAPi for clinical translation (98). The gene discussed is PARP1; the disease is glioblastoma.